Werewolf Therapeutics, Inc. (NASDAQ:HOWL) Short Interest Update

Werewolf Therapeutics, Inc. (NASDAQ:HOWL) was the target of a significant increase in short interest during the month of November. As of November 15th, there was short interest totalling 1,310,000 shares, an increase of 6.5% from the October 31st total of 1,230,000 shares. Currently, 4.0% of the company’s shares are sold short. Based on an average trading volume of 683,000 shares, the short-interest ratio is presently 1.9 days.

Werewolf Therapeutics Price Performance

NASDAQ:HOWL opened at $1.86 on Wednesday. The company has a debt-to-equity ratio of 0.29, a quick ratio of 10.10 and a current ratio of 10.10. Werewolf Therapeutics has a 12-month low of $1.58 and a 12-month high of $8.19. The stock’s fifty day simple moving average is $2.19 and its 200-day simple moving average is $2.57.

Hedge Funds Weigh In On Werewolf Therapeutics

Several institutional investors have recently modified their holdings of HOWL. SG Americas Securities LLC bought a new position in Werewolf Therapeutics during the 3rd quarter worth approximately $29,000. Point72 DIFC Ltd bought a new position in shares of Werewolf Therapeutics during the second quarter worth $34,000. XTX Topco Ltd acquired a new position in shares of Werewolf Therapeutics in the 3rd quarter valued at $45,000. Rhumbline Advisers bought a new stake in shares of Werewolf Therapeutics in the 2nd quarter valued at $79,000. Finally, American Century Companies Inc. raised its stake in Werewolf Therapeutics by 50.7% during the 2nd quarter. American Century Companies Inc. now owns 37,634 shares of the company’s stock worth $92,000 after buying an additional 12,656 shares during the period. 64.84% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright restated a “buy” rating and set a $15.00 target price on shares of Werewolf Therapeutics in a research report on Tuesday, November 19th.

About Werewolf Therapeutics

Werewolf Therapeutics, Inc, a biopharmaceutical company, develops therapeutics engineered to stimulate the body's immune system for the treatment of cancer. The company, through its proprietary PREDATOR platform, designs conditionally activated molecules that stimulate adaptive and innate immunity for addressing the limitations of conventional proinflammatory immune therapies.